ARMP Armata Pharmaceuticals, Inc.

AMEX
$3.74

Armata Pharmaceuticals, Inc. (ARMP) is expected to report earnings on November 11, 2026, after the market close. The consensus earnings estimate is a loss of $0.57 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -13.4% since its last earnings release on August 12, 2026.

Armata Pharmaceuticals Beat Consensus Estimates
Wednesday, August 12, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 11
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.57)
Rev est $900K
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $5.15

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company's principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.